Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Fineline Cube Aug 31, 2026
Company Deals

Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline

Fineline Cube Sep 28, 2023

China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured...

Company Drug

Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH

Fineline Cube Sep 28, 2023

Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47

Fineline Cube Sep 28, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...

Company Deals

MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices

Fineline Cube Sep 28, 2023

MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...

Company Drug

Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821

Fineline Cube Sep 28, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...

Company Drug

LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China

Fineline Cube Sep 28, 2023

Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...

Policy / Regulatory

Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...

Policy / Regulatory

Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments

Fineline Cube Sep 27, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene...

Company Deals

Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies

Fineline Cube Sep 27, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...

Company Drug

Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast

Fineline Cube Sep 27, 2023

Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...

Company Drug

Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment

Fineline Cube Sep 27, 2023

Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...

Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment

Fineline Cube Sep 27, 2023

United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...

Company Drug

BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02

Fineline Cube Sep 27, 2023

BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...

Company Drug

Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China

Fineline Cube Sep 27, 2023

The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...

Company

Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs

Fineline Cube Sep 27, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...

Company Deals

Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership

Fineline Cube Sep 27, 2023

Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application...

Company

Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus

Fineline Cube Sep 27, 2023

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first...

Company Medical Device

CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting

Fineline Cube Sep 27, 2023

China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative...

Policy / Regulatory

Hunchun Port Designated as Medical Materials Import Port by NMPA and GAC

Fineline Cube Sep 27, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have jointly released...

Posts pagination

1 … 514 515 516 … 714

Recent updates

  • WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
  • Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30
  • Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Company Deals

Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.